Advanced Breast Cancer
Conditions
Brief summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Detailed description
Randomized controlled trials (RCTs) are generally regarded as the gold-standard of evidence for establishing efficacy of medical products. However, real-world data (RWD) are increasingly used to complement evidence from RCTs. Yet, to have confidence in the accuracy of non-interventional studies medical products and their outcomes in oncology, investigators need to know what questions can be validly answered, with which non-interventional study designs, and which analysis methods are appropriate, given the data that is available. Building on a process from the RCT DUPLICATE initiative1-4 EmulatioN of Comparative Oncology trials with Real-world Evidence (ENCORE) is part of the expansion project specific to oncology and aims to emulate 12 randomized oncology RCTs using multiple EHR data sources. The purpose of this protocol is to describe the emulation of the MONARCH-3 trial. MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole/anastrozole, daily.
Interventions
DRUGInitiation of abemaciclib plus letrozole/anastrozole
Any doses and frequency observed in clinical practice will be allowed
DRUGInitiation of letrozole/anastrozole
Any doses and frequency observed in clinical practice will be allowed
Sponsors
Brigham and Women's Hospital
Food and Drug Administration (FDA)
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Inclusion criteria
* Female aged ≥18 years at treatment initiation from 2017 - 2023 * Evidence of metastatic breast cancer (MBC) * Documentation of Estrogen/Progesterone receptor-positive (ER/PR+) * Documentation of Human Epidermal Growth Factor Receptor Negative (HER2-) * ECOG performance status of 0 or 1 within 90 days of index date
Exclusion criteria
* CNS metastases * Prior treatment with CKD4/6 inhibitor * Prior or current treatment with chemotherapy or endocrine therapy other than letrozole/anastrozole for systemic anticancer therapy for MBC. * Prior (neo-)adjuvant endocrine therapy * Systemic anticancer therapy other than abemaciclib or letrozole/anastrozole * Non-breast cancer malignancy other than basal/squamous cell skin cancer or carcinoma in situ of cervix
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to all-cause mortality (overall survival) | From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on specialty oncology registry data provider, end of data ranges from June 2023 to April 2024) | Hazard ratio (95% CI) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to next treatment (TTNT) | From time of initiation of therapy through the earliest of TTNT, death from any cause, or end of data availability (depending on specialty oncology registry data provider, end of data ranges from June 2023 to April 2024) | Hazard ratio (95% CI) |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORShirley Wang, PhD, ScM
Brigham and Women's Hospital
PRINCIPAL_INVESTIGATORDenys Shay, MD
Brigham and Women's Hospital
Outcome results
None listed